Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial
Authors' conclusion
This study demonstrates that a 3-day course of dexamethasone substantially reduces the APR following zoledronate infusion.
Study context
- Population
- Patients receiving intravenous zoledronate
- Participants
- 60 patients
- Comparison
- 3-day course of oral dexamethasone 4 mg daily vs placebo before zoledronate
- Dexamethasonen = 30
- Placebon = 30reference
- Primary endpoint
- Temperature change from baseline
- Follow-up
- Evening following zoledronate
Methodological detailsplacebo-controlled, double-blind
- Placebo-controlled
- Double-blind
Primary result
As reported in the abstract
Dexamethasone
−0.10
mean · 95% CI −0.34–0.14 · °C
Placebo
0.84
mean · 95% CI 0.53–1.16 · °C
P < 0.0001
Further findings
Median
| Outcome | Dexamethasone | Placebo | P value |
|---|---|---|---|
| Change in APR-related symptom score · 1 day after zoledronateDifference in symptom score over time | 0 (95% CI 0–1) | 3 (95% CI 0–5) | P = 0.0005 |
Safety
Temperature increase ≥1°C to >37.5°C
P = 0.0005
Original publication
Effect of a Three-Day Course of Dexamethasone on Acute Phase Response Following Treatment With Zoledronate: A Randomized Controlled Trial. J Bone Miner Res. Published 27 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →